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ABSTRACT MEF2s transcription factors and class IIa
HDACs compose a fundamental axis for several differ-
entiation pathways. Functional relationships between
this axis and cancer are largely unexplored. We have
found that class IIa HDACs are heterogeneously ex-
pressed and display redundant activities in breast can-
cer cells. Applying gene set enrichment analysis to
compare the expression profile of a list of putative
MEF2 target genes, we have discovered a correlation
between the down-regulation of the MEF2 signature
and the aggressiveness of ER breast tumors. Kaplan-
Meier analysis in ER breast tumors evidenced an
association between increased class IIa HDACs expres-
sion and reduced survival. The important role of the
MEF2-HDAC axis in ER breast cancer was confirmed
in cultured cells. MCF7 ER cells were susceptible to
silencing of class IIa HDACs in terms of both MEF2-
dependent transcription and apoptosis. Conversely, in
ER MDA-MB-231 cells, the repressive influence of
class IIa HDACs was dispensable. Similarly, a class IIa
HDAC-specific inhibitor preferentially promoted the
up-regulation of several MEF2 target genes and apopto-
sis in ER cell lines. The prosurvival function of class
IIa HDACs could be explained by the repression of
NR4A1/Nur77, a proapoptotic MEF2 target. In sum-
mary, our studies underscore a contribution of class IIa
HDACs to aggressiveness of ER tumors.—Clocchiatti,
A., Di Giorgio, E., Ingrao, S., Meyer-Almes, F.-J., Tri-
podo, C., Brancolini, C. Class IIa HDACs repressive
activities on MEF2-depedent transcription are associ-
ated with poor prognosis of ER breast tumors.
FASEB J. 27, 942–954 (2013). www.fasebj.org
Key Words: KLF2  proliferation  Nur77  apoptosis  GSEA
Class IIa histone deacetylases (HDACs; HDAC4,
HDAC5, HDAC7, and HDAC9) are characterized by
homology with the yeast enzyme Hda1, tissue-specific
expression/functions, and nuclear-cytoplasmic shut-
tling (1). Cytoplasmic localization of class IIa is coupled
to transcriptional activation, while nuclear accumula-
tion promotes transcriptional repression (2). Nuclear-
cytoplasmic shuttling is monitored by various kinases
that can phosphorylate class IIa HDACs at 14-3-3 bind-
ing sites (3, 4). Other post-translational modifications,
such as: sumoylation, selective proteolysis, and poly-
ubiquitination, keep class IIa HDACs activities in check
(5, 6). In addition, their expression is also subjected to
transcriptional and translational control (7, 8). Various
transcription factors have been reported to interact
with class IIa HDACs. The most important are members
of the myocyte enhancer factor 2 (MEF2) family (9).
Several studies have certified the key role played by the
MEF2-HDAC axis during differentiation (10, 11). By
contrast, tumor-associated alterations of the axis have
been observed only recently (12–14).
Breast cancer comprises a heterogeneous group of
diseases characterized by distinct molecular aberrations
(15). Sequencing of protein-coding genes has revealed
statistically significant mutations of HDAC4 in breast
cancer (16). Other studies have reported altered expres-
sion of MEF2 members and of HDAC4 (17, 18). Despite
some available clues, the contribution of the MEF2-HDAC
axis to breast cancer is largely unexplored. In this study,
we have investigated the status of the axis in breast cancer
cell lines and tumors. Overall, our data imply that target-
ing class IIa HDACs could represent an interesting ther-
apeutic strategy for impairing proliferation of estrogen
receptor-positive (ER) aggressive tumors.
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MATERIALS AND METHODS
Cell culture, infections, and siRNA transfection
MCF-10A cells were grown as described previously (6). Breast
cancer cell lines were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% FBS plus
penicillin/streptomycin and l-glutamine, with the exception
of ZR-75-1 and HCC1937 cells, which were grown in RPMI
1640. The CRM1 inhibitor, leptomycin-B (LC Laboratories,
Woburn, MA, USA), was used at 5 ng/ml. AICAR (Sigma-
Aldrich, St. Louis, MO, USA) was used. IC50 values were
obtained using the Rezazurin test. MCF7 and MDA-MB-231
cells expressing GFP or HDAC4-GFP transgenes were gener-
ated by retroviral infection as described previously (6). Cells
were transfected 24 h after plating by adding the OptiMem
medium containing Lipofectamine plus the stealth RNAi
oligos (Invitrogen, Carlsbad, CA, USA). Cells were collected
after 48 h from transfection.
Immunohistochemistry
Sections of breast tissue, 4 m thick, were deparaffinized and
rehydrated. Subsequently, the slides were microwave-treated
in citrate buffer (pH 6; DakoCytomation, Glostrup, Den-
mark). After neutralization of the endogenous peroxidase,
sections were first incubated with protein block Novocastra
(UK) for 10 min and next with the anti-human HDAC4
(dilution 1:100). Incubation time was overnight at 4°C. Nor-
mal mouse serum was used as negative control. Staining was
performed by streptavidin-Hrp/biotyn detection system (LSAB
System-Hrp; Dako). After counterstaining with hematoxylin
(Novocastra, Newcastle upon Tyne, UK), sections were viewed
under a Leica DM3000 optical microscope (Leica Microsys-
tems, Wetzlar, Germany), and captions were collected using a
Leica DFC320 digital camera (Leica).
Immunoblotting, immunoprecipitation, and
immunofluorescence
Immunoblotting was performed as described previously (6).
Antibodies used in this work were anti: HDAC3, HDAC5 and
HDAC7 (Cell Signaling Technology, Danvers, MA, USA),
HDAC9 (Abcam, Cambridge, UK), MEF2A (Santa Cruz Bio-
technology, Santa Cruz, CA, USA), MEF2C (Cell Signaling
Technology), MEF2D and Ran (BD Biosciences, San Jose, CA,
USA), EFGR (Santa Cruz Biotechnology), and Bcl-2 (Sigma-
Aldrich). For immunoprecipitations, cells were collected di-
rectly from culture dishes with a rubber scraper into low-salt
lysis buffer (20 mM TrisHCl, pH 7.5; 2 mM EDTA; 10 mM
MgCl2; 10 mM KCl; and 1% Triton-X100) supplemented with
protease inhibitors. Lysates were incubated with antibody
against HDAC4. After incubation with protein A beads (GE
Healthcare, Little Chalfont, UK), washes were performed
with lysis buffer. For the deacetylase assay, beads were resus-
pended in the assay buffer (50 mM TrisCl, pH 8; 137 mM
NaCl; 2.7 mM KCl; and 1 mM MgCl2) and incubated with
Fluor-de-Lys Green Substrate (Enzo Life Sciences, Farm-
ingdale, NY, USA), which comprises an acetylated lysine side
chain, for 30 min at 37°C. Deacetylation of the substrate
sensitizes it so that treatment with the developer produces a
fluorophore. When added to the assay buffer, TSA was at 40
M final concentration. For immunofluorescence, cells were
fixed in 3% paraformaldehyde and permeabilized with 0.1%
Triton-X100 in PBS. Next, coverslips were incubated with
primary antibodies anti-HDAC4, anti-HMGB1 (Abcam), anti-
SMAC (6, 19), and anti-DRP-1 (BD Biosciences). Finally, they
were washed twice with PBS and incubated with 488-Alexa or
546-Alexa conjugated secondary antibodies (Invitrogen) and
TRITC-phalloidin (Sigma-Aldrich). Cells were examined with
a Leica SP confocal microscope.
RNA extraction, retrotranscription reaction, and
quantitative PCR
Cells were harvested, and RNA was obtained using TRIzol
reagent (Life Technologies, Gaithersburg, MD, USA). MMLV
reverse transcriptase (Life Technologies) was used for retro-
transcription, utilizing 1 g of total RNA for reaction. qRT-
PCR was performed using CFX96 (Bio-Rad, Hercules, CA,
USA) and SYBR green technology (Kapa Biosystems,
Woburn, MA, USA). Data were analyzed with the Ct
method, using the geometric mean of HPRT and -actin for
normalization. Data, from 3 independent experiments,
were expressed as means  se and analyzed with Student’s t
test. qRT-PCR data with the inhibitor were obtained using the
geometric mean of HPRT, -actin, and GAPDH for normaliza-
tion. All reactions were done in triplicate.
Cell cycle analysis
DNA staining was performed as described previously (6). For
S-phase analysis, cells were grown for 3 h with 100 M
bromodeoxyuridine (BrdU). After fixation, coverslips were
treated with 1 N HCl (10 min, in ice), followed by 20 min with
2 N HCl at room temperature. Mouse anti-BrdU (Sigma-
Aldrich) was used as primary antibody. Nuclei were stained
with Hoechst 33258 (Sigma-Aldrich).
Genomic DNA isolation and DNA sequencing
Genomic DNA was isolated and purified using the Qiagen kit
(Qiagen, Valencia, CA, USA). PCRs were made using primers
covering the different exons. All PCR products were se-
quenced with the Big Dye Terminator Sequencing RR-100 kit
on the ABI PRISM 310 Genetic Analyzer platform (Applied
Biosystems, Foster City, CA, USA) on both strands.
Chromatography
Cells were resuspended in the lysis buffer (50 mM TrisHCl,
pH7.5; EDTA 0.5 mM; 120 mM NaCl; and Nonidet P-40
0,5%). After centrifugation at 12,000 rpm for 10 min, the
extracts were loaded on a column packed with Superose 6
(GE Healthcare). As running buffer, 50 mM TrisHCl (pH
7.5), EDTA 0.5 mM, 120 mM NaCl, and Nonidet P-40 0.1%
was used.
Gene set enrichment analysis (GSEA)
Analyses were performed using the GSEA software (http://
www.broadinstitute.org/gsea/index.jsp). The list of putative
MEF2 target genes was obtained from the Molecular Signa-
ture Database (http://www.broadinstitute.org/gsea/msigdb/
index.jsp). At least 1000 permutations were performed using
the “genes_set” permutation type for data obtained from cell
lines or “phenotype ” permutation type for data obtained for
human tumors. Datasets for human tumors were taken from
the U.S. National Center for Biotechnology Gene Expression
Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/
geo/). For cell lines, datasets of Mori GSE15026 (20) and
Varma GSE32474 (21) were used. For human tumor samples,
datasets of Desmedt GSE7390 (22) and Pawitan GSE1456
(23) were employed.
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TCGA Kaplan-Meier analysis
Class IIa HDAC expression data were retrieved from the cBio
Cancer Genomics Portal (http://www.cbioportal.org/public-
portal/). Patients were subdivided into 2 groups: the first
consisted of patients with increased expression of at least one
member of the family (Z score 2), and with the remnant
members having a Z score between 2 and 2. In patients
that composed the second group, all class IIa HDAC members
showed a Z score between2 and2. All ER tumor samples
were taken from the PAM50 Luminal gene expression signa-
tures.
RESULTS
Expression levels of the different components of the
MEF2/HDAC axis in breast cancer cell lines
To comprehend the role of the MEF2-HDAC axis in
breast cancer, we investigated the expression of the
different components of the axis, in breast cancer cell
lines and in the nontransformed mammary epithelial
cell line, MCF-10A (Fig. 1A–C). The selected cell lines
recapitulate genetic alterations commonly observed in
breast cancer (Supplemental Table S1). Class IIa
HDACs are heterogeneously expressed, and an associ-
ation between class IIa levels and a breast cancer cell
type cannot be evoked. HDAC5 and HDAC9 show the
highest expression in luminal cell line T47D. By con-
trast, HDAC4 levels are elevated in the basal MDA-MB
series. Also, HDAC7 is highly expressed in the triple-
negative cells, with a peak in the BRCA1-mutated
HCC1937 cells, where HDAC4 is almost undetectable
(Fig. 1A–C). MEF2 transcription factors present a more
homogenous pattern of expression. MEF2C is ex-
pressed at similar levels in all tested breast cancer cell
lines, whereas MEF2A and MEF2D expression show
some complementarity, well evident in SK-BR-3 and
MCF-10A cells.
Immunofluorescence analysis was used to define the
subcellular localization of HDAC4. We focused our
attention on this deacetylase because it is highly ex-
pressed in several basal cell lines, and mutations have
been reported in breast cancer (16). To evaluate
HDAC4 nuclear-cytoplasmic shuttling, cells were also
treated with leptomycin B, an inhibitor of nuclear
export. HDAC4 positivity was validated by siRNA trans-
fection (data not shown). In almost all cancer cell lines,
HDAC4 shows a diffuse nuclear-cytoplasmic (pancellu-
lar) or cytoplasmic localization (Fig. 1D). Suppression
of nuclear export rapidly promoted its nuclear accumu-
lation, with the exception of MDA-MB-468 cells (Fig.
1D). Figure 1E exemplifies the analysis performed,
showing the data for the luminal cell line MCF7 and the
basal cell line MDA-MB-468. These results indicate that
in all the tested cell lines, HDAC4 shuttles continuously
between the nucleus and cytoplasm, and in MDA-MB-
468 cells, there is a defect in its nuclear import.
To evaluate mutations of HDAC4 in the investigated
breast cancer cell lines, we sequenced its coding region,
from exon 2 to exon 27. Homozygous variations in the
HDAC4 coding sequence were found in HCC1937,
ZR-75-1, SK-BR-3 and the three MDA-MB cell lines
(Supplemental Table S2). However, only in HCC1937
cells was a missense mutation (A786T in exon 18)
found. To evaluate HDAC4 levels in breast tumors,
immunohistochemistry analysis was performed on 21
cases (Supplemental Fig. S1 and Supplemental Table
S3). We evaluated the intensity of HDAC4 staining and
its subcellular localization. Similar to breast cancer cell
lines, HDAC4 levels are highly variable among different
breast tumors, without significant correlations with the
proliferative rate or the ER and progesterone receptor
(PR) status. Likewise, HDAC4 subcellular localization
shows profound variations among the different samples
but again without evident correlations with the clinical
markers.
Class IIa HDACs-repressive influence on
MEF2-dependent transcription in breast cancer cell lines
Because multiple alterations (nuclear-cytoplasmic shut-
tling, expression levels, point mutations) could poten-
tially affect HDAC4 functions, a simple correlation
between breast cancer aggressiveness and HDAC4 lev-
els could be misleading. In principle, to be relevant,
any alteration affecting HDAC4 in tumors should affect
its repressive activity. According to this hypothesis, we
decided to use HDAC4-repressive activity as a tool to
unveil its correlation with breast cancer. Krüppel-like
factor 2 (KLF2) is a well-known transcriptional target of
the MEF2-HDAC axis (6, 24). We utilized KLF2 as a
marker to estimate HDAC4-repressive influence. For
these studies, we selected MCF7 and MDA-MB-231 cell
lines as examples of luminal ER and triple-negative
cells.
To understand the role of HDAC4 in the regulation
of KLF2 expression in breast cancer cells, MCF7 and
MDA-MB-231 cells were silenced for HDAC4, and the
mRNA level of the MEF2 target gene was measured by
qRT-PCR. In both cell lines, KLF2 expression was not
significantly affected by the down-regulation of HDAC4
(Fig. 2A). The effectiveness of HDAC4 silencing was
also verified by immunoblot (data not shown). Al-
though HDAC4 is abundantly expressed in several
breast cancer cell lines, other members of the family
are expressed as well. These deacetylases could interact
with MEF2s and overcome the down-regulation of
HDAC4. Moreover, compensatory mechanisms have
been reported when the expression of a single member
of this family is silenced (25). Therefore, we investi-
gated whether silencing of HDAC4 elicited the up-
regulation of HDAC5, HDAC7 and HDAC9. As shown
in Fig. 2B, in MCF7 cells, silencing of HDAC4 triggered
the up-regulation of HDAC5, but not of HDAC7 and
HDAC9. This response was not observed in MDA-MB-
231 cells.
To investigate the role of class IIa HDACs, we de-
cided to silence simultaneously at least 3 members. We
focused our attention on HDAC4, HDAC5, and HDAC9,
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because they are phylogenetically closer. The effective-
ness of the different siRNAs was also verified by immu-
noblot (data not shown). KLF2 mRNA was still unper-
turbed in MDA-MB-231 cells with down-regulated
HDAC4, HDAC5, and HDAC9. By contrast, in MCF7
cells, the expression of the MEF2 target, KLF2, was
Figure 1. Analysis of HDAC class IIa expression in breast cancer cell lines. A) Cellular lysates of indicated breast cancer cell
lines were subjected to immunoblot analysis using the specific antibodies. CRADD was used as loading control. B) Cellular
lysates of indicated cell lines were subjected to immunoblot analysis using the specific antibodies. CRADD was used as
loading control. C) Cellular lysates of the indicated breast cancer cell lines were subjected to immunoblot analysis using
the specific antibodies. D) Quantitative analysis of HDAC4 subcellular localization in the indicated cell lines. Immuno-
fluorescence analyses were performed as described in Materials and Methods to visualize HDAC4. When used, leptomycin
B was added for 1 h. Approximately 300 cells, from 3 independent experiments, were scored. Data represent arithmetic
means  sd. E) Confocal pictures exemplifying the subcellular localization of HDAC4. Leptomycin B was added for 1 h
as indicated. Immunofluorescence analysis was performed to visualize HDAC4 subcellular localization. TRITC-phalloidin
was used to decorate actin filaments.
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up-regulated (Fig. 2C). To verify this result, we
generated MCF7 and MDA-MB-231 cells stably ex-
pressing HDAC4-GFP or GFP alone. qRT-PCR analy-
sis confirmed that in MCF7 cells, KLF2 is regulated by
HDAC4. Surprisingly, KLF2 expression was up-regu-
lated in MDA-MB-231 cells expressing HDAC4-GFP
(Fig. 2D). However, it should be taken into account
that retroviral infection with HDAC4-GFP elicited a
strong inhibition of cell growth, as previously ob-
served (26), which results in the selection of few
clones positive for HDAC4. Hence, we used an
alternative strategy to corroborate the differential
requirement of class IIa HDACs, in the two cell lines.
To release class IIa HDACs-mediated repression, we
Figure 2. Regulation of KLF2 expression by class IIa HDACs in breast cancer cells. A) qRT-PCR analysis was performed to
quantify mRNA levels of the MEF2 target gene KLF2 and of HDAC4 to verify silencing efficiency. GAPDH was used as control
gene. MCF7 and MDA-MB-231 cells transfected with siRNA against HDAC4 were lysed, and mRNAs were extracted. Fold
induction was calculated as the ratio relative to control siRNA-transfected cells. B) qRT-PCR analysis was performed to quantify
mRNA levels of HDAC4, HDAC5, HDAC7, and HDAC9. GAPDH was used as control gene. MCF7 and MDA-MB-231 cells
transfected with siRNA against HDAC4 were lysed, and mRNAs were extracted. Fold induction was calculated as the ratio relative
to control siRNA-transfected cells. C) qRT-PCR analysis was performed to quantify mRNA levels of the MEF2 target gene KLF2
and of HDAC4, HDAC5, and HDAC9 to verify silencing efficiency. GAPDH was used as control gene. MDA-MB-231 and MCF7 cells
cotransfected with siRNAs against HDAC4, HDAC5, and HDAC9 or with the same amount of a control siRNA were lysed, and
mRNAs were extracted. Fold induction was calculated as the ratio relative to control siRNA-transfected cells. D) MCF7 and
MDA-MB-231 cells expressing HDAC4-GFP or GFP were lysed, and mRNAs were extracted. qRT-PCR analysis was performed to
quantify mRNA levels of KLF2. Fold induction was calculated as the ratio relative to GFP-tramsfected cells. MCF7 and
MDA-MB-231 cells were treated with AICAR (200 M) for 24 h. qRT-PCR analysis was performed to quantify mRNA levels of
KLF2. GAPDH was used as control gene. Fold induction was calculated as the ratio relative to untreated cells. E) After 24 h from
HDAC4, HDAC5, HDAC9, and control silencing, cells were transfected with 3xMEF2-Luc reporter (1 g) and the internal
control luciferase reporter pRL-CMV (20 ng) to normalize the transfection efficiency. Assays were performed 24 h later.
F) qRT-PCR analysis was performed to quantify mRNA levels of the MEF2 target gene KLF2. GAPDH was used as control gene.
MCF7 cells cotransfected with the indicated combinations of siRNAs against HDAC4, HDAC5, and HDAC9 or with the same
amount of a control siRNA were lysed, and mRNAs were extracted. Fold induction was calculated as the ratio relative to control
siRNA-transfected cells. Data are from 3 independent experiments. *P  0.05; **P  0.01; ***P  0.005.
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promoted their export through the engagement of
the AMP-activated protein kinase (AMPK; ref. 25).
MDA-MB-231 and MCF7 cells were treated with the
AMPK activator AICAR, and mRNA was isolated for
qRT-PCR analysis. KLF2 levels were up-regulated
after AICAR treatment only in MCF7 cells. Finally,
transcription from a MEF2 artificial promoter was
selectively augmented in MCF7 cells silenced for the
different HDACs (Fig. 2E).
To elucidate which deacetylases are implicated in the
repression of KLF2 expression in MCF7 cells, we eval-
uated the combination of two different siRNAs. As
illustrated in Fig. 2F, silencing of two HDACs at a time
was sufficient to up-regulate KLF2 levels, although less
potently compared to the triple siRNA. Individual
silencing of HDAC5 or HDAC9 was not sufficient to
augment KLF2 mRNA (data not shown). We also
reduced repressive influence of the HDAC4 multi-
protein complex, and a different transcriptional reg-
ulation limited the effeact of class IIa HDACs on
KLF2 expression in MDA-MB-231 cells. Class IIa
HDACs seem to be dispensable for the control of
KLF2 transcription in MDA-MB-231 cells. Hence, in
the triple-negative cell line, the MEF2-HDAC axis
could be altered. To answer this question, we initially
compared the capability of class IIa HDACs to form a
complex with MEF2s. Coimmunoprecipitation showed that
in both cell lines, HDAC4 can be isolated in a
complex with MEF2D (Fig. 3A).
HDAC4 represses transcription by bridging the enzy-
matically active SMRT/N-CoR-HDAC3 complex to tar-
get promoters (27). After fractionation of cellular
extracts overexpressing HDAC4 on a superose 6 col-
umn, enzymatic activity was found in a high-molecular-
weight (HMW) complex with mass  0.66 MDa (27).
Hence, we investigated whether endogenous HDAC4
also could be isolated in an HMW complex and
whether differences could be appreciated between the
two cell lines. Immunoblotting of the different frac-
tions visualized for HDAC4, MEF2D and HDAC3 are
shown in Fig. 3B. Overall, the pattern is similar in the
two cell lines. Only limited amounts of HDAC4 and
MEF2D were visualized in fractions of 0.66 MDa. By
contrast, HDAC3 was almost entirely found in frac-
tions  0.66 MDa.
To confirm that MEF2D and HDAC4 can interact in
an HMW complex, the different fractions were immu-
noprecipitated for HDAC4 and visualized for MEF2D.
We performed this experiment in MDA-MD-231 cells
that express higher amounts of HDAC4. An enrich-
ment of MEF2D in the 0.66-MDa complex and a
reduction in the low-molecular-weight fractions can be
appreciated in Fig. 3B. In summary, these studies
indicate that in both cell lines, HDAC4 binds MEF2D
and can form protein complexes of mass  0.66
MDa. Theoretically, in both cell lines, HDAC4 should
be competent for suppressing MEF2-dependent tran-
scription.
To prove this assumption, we analyzed the deacety-
lase activity associated with HDAC4. Protein com-
plexes containing HDAC4 were isolated using anti-
HDAC4 antibody, and deacetylase activity was scored
using an acetyl lysine as substrate. The deacetylase
activity associated with HDAC4 was higher in MCF7
compared to MDA-MB-231 cells (Fig. 3C). This dif-
ference was even more impressive considering that
much more HDAC4 was immunoprecipitated from
MDA-MB-231 cells (Fig. 3D). Normalization of the
enzymatic activity, relative to the amount of immu-
noprecipitated HDAC4, evidenced a 5-fold increase
of HDAC4-associated deacetylase activity in MCF7
cells (Fig. 3E). Since HDAC3 provides an important
contribution to the HDAC4-associated deacetylase
activity, we analyzed HDAC3 levels in the two cell
lines. HDAC3 levels were reduced in MDA-MB-231
compared to MCF7 cells (Fig. 3F).
Taking into account that KLF2 is a target of the
MEF2-HDAC axis in breast cancer cells and that class
IIa HDAC-repressive influence is reduced in MDA-MB-
231 cells, its expression should be elevated in MDA-MB-
231 compared to MCF7 cells. qRT-PCR analysis verified
that KLF2 expression is almost 6-fold higher in MDA-
MD-231 cells (Fig. 3G). We also evaluated whether
KLF2 is subjected to different regulation in the two cell
lines. The PI3K/AKT pathway can regulate KLF2 ex-
pression (28). Inhibition of this pathway has different
consequences on KLF2 in the two cell lines (Fig. 3H).
In MCF7 cells, the PI3K inhibitor LY294002 aug-
mented KLF2 levels, whereas in MDA-MB-231 cells, it
reduced KLF2 expression. This result indicates that
KLF2 expression is under different regulation in the
two cell lines.
Class IIa HDACs regulate survival of MCF7 cells
Having proved a repressive influence of class IIa
HDACs in MCF7 cells, we decided to explore the
contribution of these HDACs to cell proliferation. The
simultaneous down-regulation of HDAC4/5/9 signifi-
cantly affected proliferation in MCF7 but not in MDA-
MB-231 cells (Fig. 4A). Conversely, single silencing of
HDAC4 was insufficient to reduce proliferation (Sup-
plemental Fig. S2). Cytofluorimetric analysis did not
revealed overt changes in cell-cycle profiles of MCF7
cells silenced for HDAC4, HDAC5, and HDAC9 (Fig.
4B). Paradoxically, a small rise in cells replicating the
DNA was observed after BrdU staining (Fig. 4C). Next
we evaluated whether class IIa HDACs could restrain
apoptosis in MCF7 cells. Trypan blue assay revealed an
increase in cell death when HDAC4, HDAC5, and
HDAC9 levels were reduced after siRNA transfection
(Fig. 4D). Apoptosis was confirmed by scoring the
release of SMAC from mitochondria, a mitochondrial
outer membrane permeabilization marker, and the
accumulation of HMGB1 in the cytoplasm (Fig. 4E). In
both assays, down-regulation of class IIa HDACs signif-
icantly increased the percentage of cells showing apo-
ptotic features (Fig. 4F).
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Class IIa HDACs repress the expression of the
proapoptotic gene Nur77/NR4A1 in MCF7 cells
Ectopic expression of KLF2 could not trigger apoptosis
in MCF7 cells (data not shown). The nuclear orphan
receptor Nur77/NR4A1 is another transcriptional tar-
get of the MEF2-HDAC complex, and it can elicit
apoptosis (29). To gain insight on the prosurvival
activity of class IIa HDACs, we analyzed whether the
expression of Nur77 family members (Nur77/NR4A1,
Nurr1/NR4A2, and NOR1/NR4A3) is repressed by
these deacetylases in MCF7 cells. Only the expression of
Nur77/NR4A1 was significantly up-regulated when
class IIa HDACs were silenced (Fig. 5A).
Figure 3. Understanding the differential contribution of class IIa HDACs in ER (MCF7) and ER (MDA-MB-231) breast cancer cells.
A) Cellular lysates from MDA-MB-231 and MCF7 cells were immunoprecipitated using an anti-HDAC4 antibody or normal rabbit
serum (NRS). Immunocomplexes were next probed with anti-MEF2D or anti-HDAC4 antibodies, as indicated. A fraction of the lysates
before immunoprecipitation was used as input (total lysates). B) Cellular lysates from MDA-MB-231 and MCF7 cells were separated
on a Superose 6 gel-filtration column. Fractions were analyzed for the presence of HDAC4, MEF2D, and HDAC3 by immunoblotting.
Next, fractions from MDA-MB-231 cells were immunoprecipitated using the anti-HDAC4 antibody, and immunoblotting was
performed with the anti-MEF2D or anti-HDAC4 antibodies. Arrows indicate the elution positions of molecular mas standards. C)
Cellular lysates from MDA-MB-231 and MCF7 cells were immunoprecipitated using an anti-HDAC4 antibody or control rabbit
immunoglobulin (IgG). After several washes, immunocomplexes were incubated with the Fluor de Lys substrate. TSA was used at 40
M final concentration. Data are from 3 independent experiments. D) A fraction of the immunoprecipitations analyzed for the
deacetylase activity was separated by SDS-PAGE, and after immunoblotting, HDAC4 was visualized using anti-HDAC4 antibody. E)
Densitometric analysis was performed on the immunoblot in panel B to normalize HDAC activity to the amount of HDAC4 purified
from the two cell lines. F) Cellular lysates generated from MCF7 and MDA-MB-231 cell lines were subjected to immunoblot analysis
using specific antibodies as indicated. CRADD was used as loading control. G) qRT-PCR analysis was performed to compare KLF2
mRNA levels between MCF7 and MDA-MB-231 cells. Samples were normalized to HPRT, GAPDH, and -actin. Fold induction was
calculated as the ratio relative to KLF2 mRNA levels in MCF7 cells. Data are from3 independent experiments. H) qRT-PCR analysis
of KLF2 mRNA levels in MCF7 and MDA-MB-231 cells after treatment for 12 h with LY294002 (5 M). Data are from3 independent
experiments. *P  0.05; **P  0.01; ***P  0.005.
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In other cell lineages, HDAC7 plays an important
role in the regulation of Nur77/NR4A1 expression. In
MCF7 cells, silencing of HDAC7 influenced Nur77
expression only in combination with the silencing of
other class IIa HDACs (unpublished results). These
results imply that in breast cancer cells, HDAC7 affects
Nur77 expression comparably to the other members of
the family.
Next, we compared the expression levels of Nur77
family members between MCF7 and MDA-MB-231 cells.
Contrary to KLF2, Nur77 levels were dramatically re-
duced in MDA-MB-231 cells; whereas expression of
Nurr1 and NOR1 was equivalent in the two cell lines
(Fig. 5B). Similar to KLF2, in MDA-MB-231 cells, the
expression of Nur77 family members was unaffected by
the triple silencing (Fig. 5C). Finally, we verified
whether enhancing Nur77 levels in MCF7 cells could
elicit apoptosis. Nur77s fused to GFP or GFP alone were
transiently transfected in MCF7 cells, and apoptosis was
evaluated by scoring the release of SMAC from mito-
chondria. As exemplified by representative immuno-
fluorescence images (Fig. 5D) and by quantitative anal-
ysis (Fig. 5E), expression of Nur77 promoted SMAC
release from mitochondria. The increase in apoptosis
was confirmed by the elevated rate of procaspase-3
processing in Nur77-overexpressing cells (Fig. 5F).
Repression of the MEF2 signature correlates with
aggressiveness of ER tumors
Our study in breast cancer cell lines suggests that
class IIa HDACs could influence MEF2-dependent
transcription in ER but not in ER tumors. To
explore this hypothesis, we compared the MEF2-
trancriptional signature in different breast tumors.
For this aim, we employed a list of genes that carry in
their proximal promoter the MEF2-binding site (http://
www.broadinstitute.org/gsea/msigdb/index.jsp). We de-
Figure 4. Class IIa HDACs control MCF7 cell survival. A)
MCF7 and MDA-MB-231 cells were transfected with siRNAs
against HDAC4, HDAC5, and HDAC9 or with the control
siRNA. After 48 h, cells were counted. Data are presented as
percentage of inhibition of the triple siRNAs relative to
control and are expressed as means  sd. *P  0.05. B)
MCF7 cells were transfected with siRNAs against HDAC4,
HDAC5, and HDAC9 or with the control siRNA. After 48 h,
cells were fixed, and cell cycle profiles were assessed by
FACS analysis (meanssd, n	3). C) MCF7 cells were trans-
fected with siRNAs against HDAC4, HDAC5, and HDAC9 or
with the control siRNA. After 33 h, BrdU was added for 3 h, and then cells were processed for immunofluorescence
(meanssd, n	3). D) MCF7 cells were transfected with siRNAs against HDAC4, HDAC5, and HDAC9 or with the control
siRNA. After 48 h, cell death was analyzed after Trypan blue staining (meanssd, n	3). E) Confocal images illustrating the
subcellular localization of SMAC and HMGB1 in MCF7 cells transfected with siRNAs against HDAC4, HDAC5, and HDAC9
or with the control siRNA. At 36 h after transfection, cells were fixed and processed for immunofluorescence.
TRITC-phalloidin was used to decorate actin filaments and anti-DRP1 antibodies to stain the cytoplasm. Images are shown
in pseudocolors. Arrows point to cells with released SMAC or HMGB1. F) Quantitative analysis of SMAC and HMGB1
localization as described in panel E.
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cided to exclude from the analysis MEF2 target genes
that are modulated by ER (Supplemental Fig. S3).
We began by comparing the expression levels of the
MEF2 target genes in MCF7 and MDA-MB-231 cells,
using GSEA and two different data sets (20, 21).
Figure 6A illustrates a reduction in the expression of
the MEF2 target genes in MCF7 cells compared to
MDA-MB-231 cells (P0.001 and P0.04), which
reflects the behavior of KLF2.
Next, we proved whether this correlation is also
maintained in human breast cancers. We initially em-
ployed two different data sets comparing poorly differ-
entiated tumors, classified grade 3 (G3) by histological
grade, subdivided into ER and ER. Figure 6B high-
lights that, similar to MCF7 and MDA-MB-231 cells, a
negative correlation appears between G3 ER tumors
and the MEF2 signature with respect to ER G3 tumors
(P0.025 and P0.045), using two different datasets
(22, 23).
The down-regulation of the MEF2 signature in G3
ER tumors prompted us to investigate the correlation
between the signature and the aggressiveness of ER
tumors. When we compared the MEF2-signature in G1
and G2 vs. G3 ER breast cancers, a down-regulation
was evident using two different datasets (refs. 22, 23
and Fig. 6C; P0.001, P0.001, and P0.02). On the
contrary, when the analysis was performed between G1
and G2 ER tumors, a differential correlation was not
proved (Fig. 6D). Similarly, repression of the MEF2
signature was not discerned when G2 and G3 ER
tumors were compared (Fig. 6D).
Targeting class IIa HDACs in ER breast tumors
To validate the MEF2 signature used in the GSEA, we
investigated whether modulation of class IIa HDACs
could influence the expression of these genes. For this
study, we used N-lauroyl-(l)-phenylalanine, a recently
Figure 5. Class IIa HDACs repress NR4A1/NuR77
expression in MCF7 cells. A) qRT-PCR analysis was
performed to quantify mRNA levels of the Nur77
family members NR4A1, NR4A2, and NR4A3. GAPDH
was used as control gene. MCF7 cells cotransfected with siRNAs against HDAC4, HDAC5, and HDAC9 or with the same
amount of a control siRNA were lysed, and mRNAs were extracted. Fold induction was calculated as the ratio relative to
control siRNA-transfected cells. B) qRT-PCR analysis was performed to compare NR4A1, NR4A2, and NR4A3 mRNA levels
between MCF7 and MDA-MB-231 cells. Samples were normalized to HPRT, GAPDH, and -actin. Fold induction was
calculated as the ratio relative to NR4A mRNA levels in MCF7 cells. C) qRT-PCR analysis was performed to quantify mRNA
levels of the Nur77 family members NR4A1, NR4A2, and NR4A3. GAPDH was used as control gene. MDA-MB-231 cells
cotransfected with siRNAs against HDAC4, HDAC5, and HDAC9 or with a control siRNA were lysed, and mRNAs were
extracted. Fold induction was calculated as the ratio relative to control siRNA-transfected cells. D) Confocal images
illustrating the subcellular localization of SMAC in MCF7 cells transfected with NR4A1/Nur77-GFP or with GFP alone. At
24 h after transfection, cells were fixed and processed for immunofluorescence. Anti-DRP1 antibodies were used to stain
the cytoplasm. Arrows point to cells with released SMAC. E) Quantitative analysis of SMAC localization as described in panel
D. F) Caspase-3/GFP together with Nur77-GFP or GFP alone was transiently expressed in MCF7 cells. After 24 h, cell lysates
were generated and subjected to immunoblotting using the anti-GFP antibody. *P  0.05; **P  0.01; ***P  0.005.
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identified class IIa specific histone deacetylase inhibitor
(HDI; ref. 30). The deacetylase activity associated with
immunoprecipitated HDAC4, but not with immuno-
precipitated HDAC3, was inhibited by the HDI (Sup-
plemental Fig. S4).
When MCF7 and MDA-MB-231 cells were treated
with the HDI, proliferation impairment (IC50 at 48 h:
23012 M) and cell death were observed only MCF7
cells (Fig. 7A, B). As for the siRNA experiments, growth
of MDA-MB-231 cells was unaffected by the presence of
the HDI. Next, we explored the effect of the class IIa
HDI on a panel of MEF2 targets (NR4A1, KL2, KLF3,
KLF5, MARK1, GADD45
, IPO4, PPAP2A, and USP47),
genes of the signature used in the GSEA. Figure 7C
shows that expression of several MEF2 targets was
significantly increased (2-fold) in MCF7 cells treated
with the HDI (KLF-2, NR4A1, KLF3, MARK1, and
GADD45
). This up-regulation was less evident in
MDA-MB-231 cells. Here, only KLF3 induction mim-
icked the response observed in MCF7 cells. NR4A1
induction was less prominent, whereas KLF2, MARK1,
and GADD45
 were not significantly up-regulated. By
contrast, IPO4 induction was observed only in MDA-
MB-231 cells. Of note, the HDI was a more potent
inducer of the MEF2-dependent transcription with
respect to the triple siRNA. The specificity of the
antiproliferative effect elicited by the HDI was verified
by comparing two compounds structurally resembling
specific portions of the inhibitor: l-phenylalanine-
methyl ester and dodecanoyl-(d/l)-homoserine. When
dose-dependent studies were performed in MCF7 cells
using the HDI and the two controls, effect on prolifer-
ation, induction of apoptosis, and activation of MEF2-
dependent transcription were observed only in re-
sponse to the class IIa inhibitor (Fig. 7D–F).
We also extended this study to other ER and ER
cell lines (Supplemental Fig. S5). Overall, the ER cells
were resistant to the antiproliferative effect of the HDI
and impotent in up-regulating Nur77 expression,
whereas the ER cell line (ZR-75-1) entered apoptosis
and up-regulated Nur77 expression. These results
prompted us to analyze the involvement of class IIa
HDACs in the aggressiveness of ER tumors. To begin
to answer this question, we interrogated the Cancer
Genome Atlas to find a correlation between survival
and the expression levels of class IIa HDACs. The
redundant role of class IIa HDACs inspired us to
consider the different members of the family as a single
entity. Patients with ER tumors were subdivided into
two groups: high and normal class IIa HDACs (see
Materials and Methods). Kaplan-Meier analysis showed
that patients with high class IIa HDAC expression had
a median survival of 85 mo, compared to patients with
low class IIa HDAC expression, who had a median
survival of 114 mo (Fig. 7G).
DISCUSSION
Breast cancer is a heterogeneous disease in terms of
morphological appearance, molecular features, behav-
ior, and response to therapy (24). Our studies indicate
that class IIa HDACs are heterogeneously expressed in
different subtypes of breast cancer cell lines. This
heterogeneity was also confirmed in breast tumors by
exploring public-domain databases, such as GEO and
Figure 6. Repression of MEF2 target genes in G3 ER breast tumors. GSEA is a method
that ascertains whether a set of genes shows differences between two biological conditions.
Normalized enrichment score (NES) indicates the degree to which the MEF2 gene set is
up-regulated (NES) or down-regulated (NES). Corresponding P values are indicated.
A) GSEA of 900 putative MEF2 target genes in expression data from MDA-MB-231 cells
compared with MCF7 cells. B) GSEA of 900 putative MEF2 target genes in expression data
from ER compared with ER breast tumors. C) GSEA of 900 putative MEF2 target genes
in expression data from ER G1 or G2 compared with ER G3 breast tumors. D) GSEA of
900 putative MEF2 target genes in expression data from ER G1 compared with ER G2 or from ER G2 compared with
ER G3 breast tumors.
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Oncomine, and by immunohistochemistry for HDAC4.
A second feature of class IIa HDACs was redundancy.
Class IIa HDACs act redundantly to suppress MEF2-
dependent transcription, and compensatory circuits
controlling their levels also exist (25). These character-
istics hint that searching for a correlation between
expression levels of a single member of the family and
a particular breast cancer subtype could be an oversim-
plistic approach. Hence, we used a different strategy.
We measured the contribution of class IIa HDACs to
breast cancer indirectly, by ranking the expression
levels of a list of putative MEF2 target genes. In this
manner we have found a correlation between the
down-regulation of several MEF2 targets and the ag-
gressiveness of G3 ER tumors. The association was
further delineated by Kaplan-Meier analysis. High class
IIa HDAC expression is associated with reduced survival
in patients with ER breast cancer.
Although ER positivity is generally considered a
favorable prognostic marker, a substantial proportion
of patients relapse despite endocrine therapy (31). The
genomic grade index (GGI), a signature of 97 genes
differentially expressed in breast cancers of low vs. high
histological grade, has been proposed as a prognostic
and predictive factor (32). Interestingly, patients with
ER tumors and high GGI had worse long-term recur-
rence-free survival (33). Many genes included in the
GGI and also in different prognostic signatures are
related to cell cycle and proliferation (34). Likewise, a
protein signature of PI3K activation can predict the
poor outcome of ER breast cancer (35). Interestingly,
the expression levels of the two MEF2 target genes
KLF2 and NR4A1 inversely correlate with genes that
mark cell proliferation in ER tumors (Supplemental
Table S4). Hence, it will be important to investigate
whether connections between class IIa HDACs and
Figure 7. Targeting class IIa HDACs in ER breast tumors. A) MCF7 and
MDA-MB-231 cells were treated with 100 M of the class IIa HDI N-lauroyl-
(l)-phenylalanine. After 48 h, cells were counted. Data are presented as
percentage of inhibition of the HDI relative to DMSO and are expressed as
means sd. B) MCF7 and MDA-MB-231 cells were treated with HDI (100 M).
After 48 h, cell death was analyzed after Trypan blue staining (meanssd,
n	3). C) qRT-PCR analysis was performed to evaluate the expression of a
panel of MEF2 target genes selected from the set used in the GSEA. MCF7 and
MDA-MB-231 cells were treated for 48 h with 100 M HDI. Fold induction was
calculated as the ratio relative to mRNA levels in untreated MCF7 and
MDA-MB-231 cells, respectively. 2-Microglobulin was used as control. D)
MCF7 cells were treated with the indicated concentrations of HDI and with two
compounds, structurally resembling specific portions of the inhibitor: l-phe-
nylalanine-methyl ester and dodecanoyl-(d/l)-homoserine. After 48 h, cells
were counted. Data are presented as percentage of inhibition of the different
compounds relative to DMSO and are expressed as means  sd; n 	 3. E) MCF7 cells were treated as in panel D. After 48
h, cell death was analyzed after Trypan blue staining (meanssd; n	3). F) qRT-PCR analysis was performed to evaluate the
expression of the MEF2 target genes KLF2 and NR4A1. MCF7 cells were treated for 48 h with 100 M of the indicated
compounds. Fold induction was calculated as the ratio relative to mRNA levels in untreated MCF7 cells. 2-Microglobulin
was used as control. G) Kaplan-Meier analysis based on class IIa HDACs expression using data from TCGA ER breast
cancers. All cases, n 	 372; high class IIa HDAC expression cases, n 	 29.
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signaling pathways involved in the aggressiveness of
ER tumor exist.
How might repression of MEF2 target genes by class
IIa HDACs enable more aggressive ER breast cancer
and lead to worse clinical outcomes? Experiments in
MCF7 cells suggest that class IIa HDACs could affect
cell survival. The prosurvival role of class IIa HDACs
can be exemplified by the repressive influence on
Nur77, a MEF2 target gene controlling apoptosis in
certain conditions (29). Certainly, despite the finding,
that Nur77 can assume apoptotic functions in MCF7,
involvement of other MEF2 targets is highly predict-
able. Nur77/NR4A1 belongs to the family of orphan
nuclear receptors (36). Nur77 can modulate apoptosis
through both transcription-dependent and indepen-
dent activities (37–39). Translocation of Nur77 into
mitochondria can convert Bcl-2 into a proapoptotic
factor (39), whereas in the nucleus, it can drive the
expression of proapoptotic genes (37, 38). Interest-
ingly, the prosurvival role of class IIa HDACs could have
a therapeutic perspective. A class IIa HDAC inhibitor
(30) elicited an antiproliferative response and apopto-
sis only in MCF7 and ZR-75-1 ER cells. This response
was coupled to the up-regulation of several MEF2 target
genes, with Nur77 the more reactive.
In contrast to KLF2, expression of Nur77 was dramat-
ically reduced in MDA-MB-231 cells. This result is not
surprising, since MEF2 family members depend on the
recruitment of, and cooperation with, other transcrip-
tion factors to promote transcription of their target
gene. In addition, MEF2 target genes (including KLF2
and Nurr77) can be regulated by factors alternative to
MEF2, and MEF2 activity can be influenced by mecha-
nisms in addition or alternative to class IIa HDAC
binding (40). In fact, MDA-MB-231 cells are also less
capable of augmenting Nur77 levels when class IIa
HDACs are perturbed. These cells are largely emanci-
pated from class IIa HDACs for the repression of this
MEF2 target (41).
Unlike Nur77, in the triple-negative cells and in ER
tumors, several MEF2 target genes are expressed at
higher levels compared to ER tumors. At the moment,
the reason for this different behavior is unclear. In
basal cancer cell lines, we observed that different
alterations in class IIa HDACs could in principle pro-
mote the up-regulation of these target genes: point
mutations (HCC1937), deficit in nuclear import (MDA-
MB-468), reduced deacetylase activity associated with
class IIa HDACs (MDA-MB-231). It is also possible that
the activation of alterative signaling pathways renders
superfluous the MEF2-HDAC axis. In summary, this
first work on the MEF2-HDAC axis in breast cancer is
clearly exploratory. Nonetheless, data presented here
suggest a role of this axis in modulating outcomes in
ER breast cancer.
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